Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v3-EN Version v1-EN
Language English English
Date Updated 2020-02-05 2019-12-18
Drug Identification Number 02423596 02423596
Brand name INCRUSE ELLIPTA INCRUSE ELLIPTA
Common or Proper name umeclidinium (as bromide) dry powder for oral inhalation umeclidinium (as bromide) dry powder for oral inhalation
Company Name GLAXOSMITHKLINE INC GLAXOSMITHKLINE INC
Ingredients UMECLIDINIUM UMECLIDINIUM
Strength(s) 62.5MCG 62.5MCG
Dosage form(s) POWDER POWDER
Route of administration INHALATION INHALATION
Packaging size 7's 7's
ATC code R03BB R03BB
ATC description
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2019-12-10 2019-12-10
Estimated end date 2020-02-15 2020-02-15
Actual end date 2020-02-05
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments